<?xml version="1.0"?><?xml-stylesheet type="text/xsl" href="drug-table.xslt"?><drug name = "dolutegravir tab">
<dose><value>50</value>
</dose>
<route><value>PO</value>
</route>
<strength><value>50 mg</value>
</strength>
<frequency><value>DAILY</value>
<value>BID</value>
</frequency>
<instruction></instruction>
<volume></volume>
<units><value>mg</value>
</units>
<Population><value>ADULT, CHILDREN, aged 12 to 18 AND weighing at least 40 kg.</value>
<value>ADULT</value>
</Population>
<IndicationPRN></IndicationPRN>
<AdditionalNotes><value>Recommended for treatment naïve and treatment-experienced, INI-naïve patients.</value>
<value>Recommended for treatment naïve patients when co-administered with potent UGT1A/CYP3A inducers, including efavirenz, tipranavir/ritonavir, fosamprenavir/ritonaviror rifampin.</value>
<value>Treatment-experienced, INI-resistant patients.</value>
</AdditionalNotes>
<BackgroundInformation><value>http://intraweb01.albertahealthservices.ca/Pharmacy/AHS_FORMULARY/search_details.aspx?id=8101</value>
</BackgroundInformation>
<PRNInformation></PRNInformation>
<AHSFormularyStatus><value>FR</value>
</AHSFormularyStatus>
<HighAlert></HighAlert>
</drug>